Literature DB >> 24345836

Depression subtypes in pediatric inflammatory bowel disease.

Eva M Szigethy1, Ada O Youk, David Benhayon, Diane L Fairclough, Melissa C Newara, Margaret A Kirshner, Simona I Bujoreanu, Christine Mrakotsky, Athos Bousvaros, Arvind I Srinath, David J Keljo, David J Kupfer, David R DeMaso.   

Abstract

OBJECTIVE: The association between inflammatory bowel disease (IBD) and depression provides a unique opportunity to understand the relation between systemic inflammation and depressive symptom profiles.
METHODS: Youth (n = 226) ages 9 to 17 years with comorbid IBD and depression underwent psychiatric assessment and evaluation of IBD activity. Latent profile analysis (LPA) identified depressive subgroups based on similar responses to the Children's Depression Rating Scale-Revised. Demographic factors, depression severity, anxiety, IBD activity, inflammatory markers, IBD-related medications, and illness perception were evaluated as predictors of profile membership.
RESULTS: Mean age was 14.3 years; 75% had Crohn disease; 31% were taking systemic corticosteroids. Mean depressive severity was moderate, whereas IBD activity, which reflects inflammation, was mild. LPA identified 3 subgroups: Profile-1 (mild, 75%) had diverse low-grade depressive symptoms and highest quality of life; Profile-2 (somatic, 19%) had severe fatigue, appetite change, anhedonia, decreased motor activity, and depressed mood with concurrent high-dose steroid therapy and the highest IBD activity; and Profile-3 (cognitive, 6%) had the highest rates of self-reported depressive symptoms, ostomy placements, and anxiety with IBD symptoms in the relative absence of inflammation.
CONCLUSIONS: Evidence was found for 3 depression profiles in youth with IBD and depression. Our analyses determined that patients with predominantly somatic or cognitive symptoms of depression comprised 25% of our cohort. These findings may be used to design subgroup-specific interventions for depression in adolescents with IBD and other physical illnesses associated with systemic inflammation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24345836      PMCID: PMC4113828          DOI: 10.1097/MPG.0000000000000262

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  60 in total

1.  Increased anal resting pressure and rectal sensitivity in Crohn's disease.

Authors:  Peter Andersson; Gunnar Olaison; Olof Hallböök; Bernt Boeryd; Rune Sjödahl
Journal:  Dis Colon Rectum       Date:  2003-12       Impact factor: 4.585

Review 2.  Corticosteroid-induced adverse events in adults: frequency, screening and prevention.

Authors:  Laurence Fardet; Abdulrhaman Kassar; Jean Cabane; Antoine Flahault
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

3.  Effects of corticosteroid therapy on depression and inflammation in ulcerative colitis patients.

Authors:  Burak Suvak; Yavuz Beyazit; Abdurrahim Sayilir; Serkan Torun; Ozlem Suvak
Journal:  J Crohns Colitis       Date:  2011-05-04       Impact factor: 9.071

Review 4.  Cognitive-behavioral therapy for children with comorbid physical illness.

Authors:  Rachel D Thompson; Patty Delaney; Inti Flores; Eva Szigethy
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2011-02-16

Review 5.  Treatment of cytokine-induced depression.

Authors:  Lucile Capuron; Peter Hauser; Dunja Hinze-Selch; Andrew H Miller; Pierre J Neveu
Journal:  Brain Behav Immun       Date:  2002-10       Impact factor: 7.217

6.  Adverse childhood experiences and adult risk factors for age-related disease: depression, inflammation, and clustering of metabolic risk markers.

Authors:  Andrea Danese; Terrie E Moffitt; HonaLee Harrington; Barry J Milne; Guilherme Polanczyk; Carmine M Pariante; Richie Poulton; Avshalom Caspi
Journal:  Arch Pediatr Adolesc Med       Date:  2009-12

7.  Mood disorders in inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors.

Authors:  J R Goodhand; M Wahed; J E Mawdsley; A D Farmer; Q Aziz; D S Rampton
Journal:  Inflamm Bowel Dis       Date:  2012-02-22       Impact factor: 5.325

8.  A meta-analytic review of the psychosocial adjustment of youth with inflammatory bowel disease.

Authors:  Rachel Neff Greenley; Kevin A Hommel; Justin Nebel; Tara Raboin; Shun-Hwa Li; Pippa Simpson; Laura Mackner
Journal:  J Pediatr Psychol       Date:  2010-02-01

9.  The Great Smoky Mountains Study of Youth. Goals, design, methods, and the prevalence of DSM-III-R disorders.

Authors:  E J Costello; A Angold; B J Burns; D K Stangl; D L Tweed; A Erkanli; C M Worthman
Journal:  Arch Gen Psychiatry       Date:  1996-12

10.  Depression and IL-6 blood plasma concentrations in advanced cancer patients.

Authors:  Colleen M Jacobson; Barry Rosenfeld; Hayley Pessin; William Breitbart
Journal:  Psychosomatics       Date:  2008 Jan-Feb       Impact factor: 2.386

View more
  19 in total

1.  Depression Is Associated With More Aggressive Inflammatory Bowel Disease.

Authors:  Bharati Kochar; Edward L Barnes; Millie D Long; Kelly C Cushing; Joseph Galanko; Christopher F Martin; Laura E Raffals; Robert S Sandler
Journal:  Am J Gastroenterol       Date:  2017-11-14       Impact factor: 10.864

2.  Considering the Bidirectional Pathways Between Depression and IBD: Recommendations for Comprehensive IBD Care.

Authors:  Laurie Keefer; Sunanda V Kane
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-03

Review 3.  Influence of environmental factors in the development of inflammatory bowel diseases.

Authors:  Evangelia Legaki; Maria Gazouli
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

4.  Psychological Factors May Play an Important Role in Pediatric Crohn's Disease Symptoms and Disability.

Authors:  Miranda A L van Tilburg; Robyn Lewis Claar; Joan M Romano; Shelby L Langer; Douglas A Drossman; William E Whitehead; Bisher Abdullah; Rona L Levy
Journal:  J Pediatr       Date:  2017-02-24       Impact factor: 4.406

5.  Beta-adrenergic receptor mediated inflammation control by monocytes is associated with blood pressure and risk factors for cardiovascular disease.

Authors:  Suzi Hong; Stoyan Dimitrov; Tiefu Cheng; Laura Redwine; Christopher Pruitt; Paul J Mills; Michael G Ziegler; J Michael Green; Farah Shaikh; Kathleen Wilson
Journal:  Brain Behav Immun       Date:  2015-08-20       Impact factor: 7.217

Review 6.  Pediatric inflammatory bowel disease and depression: treatment implications.

Authors:  Divya Keethy; Christine Mrakotsky; Eva Szigethy
Journal:  Curr Opin Pediatr       Date:  2014-10       Impact factor: 2.856

7.  Effects of a Cognitive Behavioral Therapy Intervention Trial to Improve Disease Outcomes in Children with Inflammatory Bowel Disease.

Authors:  Rona L Levy; Miranda A L van Tilburg; Shelby L Langer; Joan M Romano; Lynn S Walker; Lloyd A Mancl; Tasha B Murphy; Robyn L Claar; Shara I Feld; Dennis L Christie; Bisher Abdullah; Melissa M DuPen; Kimberly S Swanson; Melissa D Baker; Susan A Stoner; William E Whitehead
Journal:  Inflamm Bowel Dis       Date:  2016-09       Impact factor: 5.325

8.  Effect of Psychotherapy on Health Care Utilization in Children With Inflammatory Bowel Disease and Depression.

Authors:  Divya Keerthy; Ada Youk; Arvind I Srinath; Nasuh Malas; Simona Bujoreanu; Athos Bousvaros; David Keljo; David R DeMaso; Eva M Szigethy
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-12       Impact factor: 2.839

9.  Major depressive disorder, suicidal behaviour, bipolar disorder, and generalised anxiety disorder among emerging adults with and without chronic health conditions.

Authors:  M A Ferro
Journal:  Epidemiol Psychiatr Sci       Date:  2015-09-08       Impact factor: 6.892

10.  Association Between Affective-Cognitive Symptoms of Depression and Exacerbation of Crohn's Disease.

Authors:  Lawrence S Gaines; James C Slaughter; Sara N Horst; David A Schwartz; Dawn B Beaulieu; Kirsten L Haman; Li Wang; Christopher F Martin; Millie D Long; Robert S Sandler; Michael D Kappelman
Journal:  Am J Gastroenterol       Date:  2016-04-05       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.